Probiotic (VSL#3) for Gulf War Illness

Abstract

The overall objective of the study was to determine whether Bifidobacterium infantis 35624 (Align ) will improve symptoms of GW illness. We have not started the study as yet. We were unable to get IND (Investigational New Drug) number for the probiotic, Bifidobacterium infantis 35624 (Align ). We requested the Department of Defense to allow us to use another commonly used probiotic, VSL#3. The Department of Defense contract has been modified to include this change. The Confidentiality Disclosure Agreement between VSL Pharmaceuticals and the Department of Veterans Affairs has been agreed. We have received IND from the Food and Drug Administration (FDA) for VSL#3. Our application is with University of Utah Institutional Review Board at the final stages of approval. This application will be sent to Department of Defense for their approval before starting the study.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2012
Accession Number
ADA570986

Entities

People

  • Ashok K Tuteja

Organizations

  • Western Institute For Biomedical Research

Tags

DTIC Thesaurus Topics

  • Actinobacteria
  • Anxiety Disorders
  • Biomedical Research
  • Colonic Diseases
  • Contracts
  • Department Of Defense
  • Department Of Veterans Affairs
  • Governments
  • Gut Microbiome
  • Institutional Review Board
  • Intestinal Diseases
  • Persian Gulf Syndrome
  • Traumatic Stress Disorder
  • Universities

Fields of Study

  • Medicine

Readers

  • Government and Public Administration Law.
  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.